David Miles

Summary

Country: UK

Publications

  1. doi request reprint Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials
    David Miles
    Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, London HA6 2RN, United Kingdom
    J Clin Oncol 29:83-8. 2011
  2. ncbi request reprint Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor
    Hannah M Simonds
    Mount Vernon Cancer Centre, Department of Oncology, Rickmansworth Road, Northwood, HA6 2RN, UK
    Expert Opin Biol Ther 7:487-91. 2007
  3. pmc Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
    David Miles
    Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK
    Breast Cancer Res Treat 142:89-99. 2013
  4. pmc Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    D W Miles
    Mount Vernon Cancer Centre, Northwood, London, HA6 2RN, UK
    Br J Cancer 108:1052-60. 2013
  5. pmc Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Rickmansworth Road, Middlesex HA6 2RN, UK
    Breast Cancer Res 11:208. 2009
  6. doi request reprint Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    J Clin Oncol 28:3239-47. 2010
  7. ncbi request reprint Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial
    David Miles
    Guy s and St Thomas Hospital, London, UK
    Clin Breast Cancer 5:273-8. 2004
  8. doi request reprint Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review
    David Miles
    Mount Vernon Cancer Centre, Northwood, UK
    Eur J Cancer 48:482-91. 2012
  9. pmc Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
    David Miles
    Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom
    Oncologist 16:1092-100. 2011
  10. ncbi request reprint Combination versus sequential single-agent therapy in metastatic breast cancer
    David Miles
    ICRF Breast Cancer Biology Unit, Guy s and St Thomas Hospital, London, UK
    Oncologist 7:13-9. 2002

Detail Information

Publications14

  1. doi request reprint Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials
    David Miles
    Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, London HA6 2RN, United Kingdom
    J Clin Oncol 29:83-8. 2011
    ....
  2. ncbi request reprint Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor
    Hannah M Simonds
    Mount Vernon Cancer Centre, Department of Oncology, Rickmansworth Road, Northwood, HA6 2RN, UK
    Expert Opin Biol Ther 7:487-91. 2007
    ..This review briefly summarises the use of trastuzumab in advanced breast cancer and describes recent studies of its use in the adjuvant setting...
  3. pmc Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
    David Miles
    Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK
    Breast Cancer Res Treat 142:89-99. 2013
    ..The efficacy and safety data reported in CLEOPATRA suggest that the combined use of pertuzumab, trastuzumab, and docetaxel should not be limited by patient age...
  4. pmc Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    D W Miles
    Mount Vernon Cancer Centre, Northwood, London, HA6 2RN, UK
    Br J Cancer 108:1052-60. 2013
    ..However, identification of patients benefitting most from bevacizumab remains elusive. The AVADO trial included an extensive optional exploratory biomarker programme...
  5. pmc Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Rickmansworth Road, Middlesex HA6 2RN, UK
    Breast Cancer Res 11:208. 2009
    ..The novel agents bevacizumab and ixabepilone were recently approved for metastatic breast cancer, and numerous other agents are currently in clinical development that may contribute further valuable therapeutic options...
  6. doi request reprint Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    J Clin Oncol 28:3239-47. 2010
    ..5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial...
  7. ncbi request reprint Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial
    David Miles
    Guy s and St Thomas Hospital, London, UK
    Clin Breast Cancer 5:273-8. 2004
    ....
  8. doi request reprint Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review
    David Miles
    Mount Vernon Cancer Centre, Northwood, UK
    Eur J Cancer 48:482-91. 2012
    ..We also examine ongoing trials investigating capecitabine-bevacizumab combination therapy...
  9. pmc Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
    David Miles
    Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom
    Oncologist 16:1092-100. 2011
    ..Secondary endpoints included vaccine safety and immune response...
  10. ncbi request reprint Combination versus sequential single-agent therapy in metastatic breast cancer
    David Miles
    ICRF Breast Cancer Biology Unit, Guy s and St Thomas Hospital, London, UK
    Oncologist 7:13-9. 2002
    ..This article expands on these issues by reviewing trials comparing combination regimens with sequential approaches...
  11. ncbi request reprint Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles
    David Miles
    Mount Vernon Cancer Centre, Northwood, Middlesex, England
    Drugs 67:1800-1. 2007
  12. ncbi request reprint Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer
    David Miles
    ICRF Clinical Oncology Unit, Guy s Hospital, London, UK
    Clin Breast Cancer 3:S134-8. 2003
    ..The trial was closed to enrollment in March 2001 with the accrual of 1030 women. The final analysis is event driven and is expected to commence mid 2003...
  13. ncbi request reprint Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain
    Tim Plunkett
    Breast Cancer Biology Group, Cancer Research UK, 3rd Floor Thomas Guy House, Guy s Hospital, London, UK
    Int J Cancer 109:691-7. 2004
    ..C57Bl/6xBALB/c hybrids were, however, well protected against both H2(d) and H2(b) expressing tumour challenge, emphasizing the importance of the host background...
  14. pmc Update on the use of aromatase inhibitors in early-stage breast cancer
    Georgios Kesisis
    Mount Vernon Cancer Centre, Rickmansworth, Northwood, Middlesex, HA6 2RN, UK
    Breast Cancer Res 11:211. 2009
    ..This review provides updates on the clinical trials of aromatase inhibitors in early breast cancer and tries to provide practical clinical guidance on their optimal use...